Activation of Src and Src-associated signaling pathways in relation to hypoxia in human cancer xenograft models

✍ Scribed by Nhu-An Pham; Joao M.M.M. Magalhaes; Trevor Do; Joerg Schwock; Neesha Dhani; Ping-Jiang Cao; Richard P. Hill; David W. Hedley

• Publisher: John Wiley and Sons
• Year: 2009
• Tongue: French
• Weight: 358 KB
• Volume: 124
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.23912

✦ Synopsis

Abstract

The hypoxic response in vitro involves alterations in signaling proteins, including Src, STAT3 and AKT that are considered to be broadly pro‐survival. The involvement of these signaling proteins in the hypoxic microenviroments that occur in solid tumors was investigated by the use of multicolor fluorescence image analysis to colocalize signaling proteins and regions of hypoxia in 4 human tumor xenografts, pancreatic carcinoma BxPC3 and PANC1 and cervical squamous cell carcinoma ME180 and SiHa. Expression levels of total Src protein (mean intensity × labeled region fraction) were higher in hypoxic regions, identified using the nitroimidazole probe EF5, relative to non‐EF5 regions in all 4 tumor models. This was associated with higher levels of phosphorylated (p‐) ^Y419^p‐Src and its substrate ^Y861^p‐FAK in EF5 positive regions of BxPC3 tumors. This effect was also seen in tumor‐bearing mice continuously breathing 7% oxygen for 3 hr which markedly increased the extent of EF5 positive labeling. In contrast, the hypoxia treatment resulted in a significant decrease in ^S727^p‐STAT3 in BxPC3 xenografts and suggested that STAT3 activity is responsive to acute hypoxia, whereas Src‐FAK signaling is associated with predominantly chronically hypoxic EF5 positive regions. Src activity in both hypoxic and nonhypoxic BxPC3 tumor regions was suppressed when mice were treated with the Src inhibitor AZD0530 (25 mg/kg/day, 5 days), suggesting that both hypoxic and normoxic tumor regions are accessible to pharmacological Src inhibition. These results show that signaling pathways are responsive to tumor hypoxia in vivo, although the effects appear to differ between individual tumor types. © 2008 Wiley‐Liss, Inc.